



Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

Michele Bartoletti, MD; Sandro Pignata, MD; Domenica Lorusso, MD, PhD; Francesco Perrone, MD; Diego Zara, MD; Fabio Puglisi, MD, PhD

Introduction

The number needed to treat (NTT), defined as the number of patients who would need to be treated to prevent an additional outcome event (eg, disease progression or death), describes absolute benefit in randomized clinical trials. The NTTs were not reported in recent studies on newly diagnosed ovarian cancer in which targeted agents, including bevacizumab and poly(adenosine diphosphate)-ribose polymerase inhibitors (PARPi), have reshaped the treatment algorithm. In this way, NTT can be useful in understanding the benefit of maintenance therapies according to biomarkers' status.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Methods

In this comparative effectiveness study, the NTT for progression-free survival (PFS) was calculated inverting the risk difference between survival probabilities at 12 months in the experimental and control groups of 5 pivotal trials published from 2011 to 2022 (ICON7,¹ SOLO1,² PRIMA,³ PAOLA-1 [Platine, Avastin and Olaparib in 1st Line],⁴ and ATHENA MONO⁵). The survival probabilities were estimated using the Kaplan-Meier survival curves with Engauge Digitizer software, version 12.1 (Mark Mitchell). The assessment of NTTs was performed in all participants and according to the homologous recombination status (deficient [HRD] or proficient [HRP]) and *BRCA* gene status, when data were available. The NTTs were rounded up to the nearest whole number. Lower NTT values indicate greater benefit. The 95% CIs for NTT were calculated as a measure of uncertainty when possible.

This study followed the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) reporting guideline. The study did not require institutional review board or ethical committee review in accordance with the Common Rule because it did not involve human participants or individual patient data.

Table. Number Needed to Treat for PFS in Pivotal Trials of Newly Diagnosed Advanced Ovarian Cancer According to Biomarkers

Trial (source)	Experimental vs control treatments	NTT (95% CI)/survival probability at 12 mo, experimental vs control group, %				Follow-up, median (IQR)
		All participants	Participants with <i>BRCA1/2</i> mutation ^a	HRD status	HRP status	
ICON 7 (Perren et al, ¹ 2011)	Bevacizumab vs placebo	7 (5-10)/80 vs 65	NA	NA	NA	19.4 mo
SOLO1 (Banerjee et al, ² 2021)	Olaparib vs placebo	NA	3 (2-4)/88 vs 51	NA	NA	40.7 (34.9-42.9) mo; 4.8 (2.8-5.3) y
PRIMA (González-Martín et al, ³ 2019)	Niraparib vs placebo	6 (4-11)/53 vs 35	3 (NA)/75 vs 44	3 (NA)/66 vs 37	8 (NA)/33 vs 20	13.8 (1-28) mo
PAOLA-1 (Ray-Coquard et al, ⁴ 2019)	Olaparib plus bevacizumab vs bevacizumab	8 (5-19)/78 vs 66	6 (3-13)/93 vs 75	7 (3-204)/83 vs 68	No PFS benefit demonstrated	22.9 (18.0-27.7) mo
ATHENA MONO (Monk et al, ⁵ 2022)	Rucaparib vs placebo	5 (3-12)/61 vs 42	3 (2-14)/81 vs 52	5 (2-58)/65 vs 44	7 (3-52)/50 vs 36	26.1 (24-27.7) mo

Abbreviations: HRD, homologous recombination deficient; HRP, homologous recombination proficient; NA, not available; NTT, number needed to treat; PFS, progression-free survival.

^a Excluding germline and somatic *BRCA* mutations.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Results

In ICON7,¹ which tested the addition of bevacizumab to a platinum-based combination treatment against placebo, the NNT in all participants was 7 (95% CI, 5-10), whereas a nonproportional hazard ratio (HR) of 0.81 (95% CI, 0.70-0.94) was reported at the primary analysis (19.4 months follow-up). In SOLO1,² olaparib was tested against placebo in *BRCA1/2*-mutated ovarian cancer. The NNT was 3 (95% CI, 2-4) at both the first (40.7 months) and second (4.8 years) analyses, with an HR of 0.30 (95% CI, 0.23-0.41). In PRIMA,³ niraparib was tested against placebo, and the NNTs were 6 (95% CI, 4-11) in all participants and 3 in those with *BRCA1/2* mutations. In PAOLA-1,⁴ olaparib plus bevacizumab was tested against bevacizumab alone, and the NNTs were 8 (95% CI, 5-19) in all participants and 6 (95% CI, 3-13) in patients with *BRCA1/2* mutations. In ATHENA MONO,⁵ rucaparib was tested against placebo, and the NNTs were 5 (95% CI, 3-12) in all participants and 3 (95% CI, 2-14) in patients with *BRCA1/2* mutations. Additionally, in PRIMA³ and ATHENA MONO,⁵ with statistically significant PFS in patients with HRP status, the NNTs were 8 with an HR of 0.68 (95% CI, 0.49-0.94) for niraparib and 7 (95% CI, 3-52) with an HR of 0.65 (95% CI, 0.45-0.95) for rucaparib (Table).

Discussion

These findings suggest that the magnitude of benefit from targeted therapies in newly diagnosed ovarian cancer is deeply affected by the biomarkers' status. Patients with *BRCA* mutations benefit most from PARPi, and adding bevacizumab seems to provide no further advantages. A PARPi-based targeted therapy is also recommended in patients with HRD status, given the clear benefit in avoiding disease progression. In this case, the choice of adding bevacizumab to olaparib vs niraparib or rucaparib alone should also consider potential adverse effects, contraindications, local reimbursement policy, and postprogression strategy. For patients with HRP status, a growing body of evidence supports the use of PARPi, and other mechanisms of action of PARPi beyond synthetic lethality should be unveiled. However, cross-trial comparisons should be conducted with caution because the characteristics of patients included in these trials and follow-up length were different. Finally, despite the actual treatment algorithm largely based on PFS data, PFS has not been established as a surrogate end point for overall survival (at least at a trial level and before the introduction of targeted agents),⁶ and in the recurrent setting, niraparib as maintenance and rucaparib as active therapies have failed to demonstrate survival benefits. Future research should discover disease vulnerability in the HRP subgroup.

ARTICLE INFORMATION

Accepted for Publication: October 20, 2022.

Published: December 2, 2022. doi:10.1001/jamanetworkopen.2022.45077

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2022 Bartoletti M et al. *JAMA Network Open*.

Corresponding Author: Michele Bartoletti, MD, Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081 PN, Italy (michele.bartoletti@cro.it).

Author Affiliations: Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy (Bartoletti, Zara, Puglisi); Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy (Pignata); Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (Lorusso); Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, Rome, Italy (Lorusso); Clinical Trials Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy (Perrone); Department of Medicine, University of Udine, Udine, Italy (Zara, Puglisi).

Author Contributions: Drs Bartoletti and Zara had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Bartoletti, Lorusso, Puglisi.

Acquisition, analysis, or interpretation of data: Bartoletti, Pignata, Perrone, Zara, Puglisi.

Drafting of the manuscript: Bartoletti.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Bartoletti, Zara, Puglisi.

Supervision: All authors.

Conflict of Interest Disclosures: Dr Bartoletti reported serving on the advisory board of GSK PLC outside the submitted work. Dr Pignata reported receiving grant funding and personal fees from Roche, Merck and Co Inc, AstraZeneca, and Pfizer Inc and personal fees from Clovis Oncology, GSK PLC, and PharmaMar during the conduct of the study. Dr Lorusso reported receiving grant funding from GSK PLC, Clovis Oncology, Genmab A/S, and Merck and Co Inc, during the conduct of the study and receiving personal fees from Amgen Inc, AstraZeneca, Clovis Oncology, Merck and Co Inc, and PharmaMar outside the submitted work. Dr Perrone reported receiving personal fees from Bayer AG, Ipsen, AstraZeneca, Bristol-Myers Squibb Co, Sandoz International GmbH, Incyte, Celgene Corp, Pierre Fabre, and Janssen-Cilag AG and grant funding to his institution from AstraZeneca, Bayer AG, Roche, Merck and Co Inc, Pfizer Inc, Incyte, Sanofi AS, BioClin, and Tesaro Inc outside the submitted work. Dr Puglisi reported grant funding from Eisai Co Ltd, Roche, and AstraZeneca and personal fees from Eisai Co Ltd, Roche, AstraZeneca, Novartis AG, Eli Lilly and Co, Daiichi Sankyo Co Ltd, Viatrix Inc, Amgen Inc, Gilead Sciences Inc, Merck and Co Inc, Pierre-Fabre, Pfizer Inc, Seagen Inc, and Viatrix Inc outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by the Italian Ministry of Health (Ricerca Corrente) and by 5 × 1000 per la Ricerca Sanitaria.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See the [Supplement](#).

REFERENCES

1. Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*. 2011;365(26):2484-2496. doi:10.1056/NEJMoa1103799
2. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2021;22(12):1721-1731. doi:10.1016/S1470-2045(21)00531-3
3. González-Martín A, Pothuri B, Vergote I, et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*. 2019;381(25):2391-2402. doi:10.1056/NEJMoa1910962
4. Ray-Coquard I, Pautier P, Pignata S, et al; PAOLA-1 Investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med*. 2019;381(25):2416-2428. doi:10.1056/NEJMoa1911361
5. Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). *J Clin Oncol*. Published online June 6, 2022. doi:10.1200/JCO.22.01003
6. Paoletti X, Lewsley LA, Daniele G, et al; Gynecologic Cancer InterGroup (GCIg) Meta-analysis Committee. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. *JAMA Netw Open*. 2020;3(1):e1918939. doi:10.1001/jamanetworkopen.2019.18939

SUPPLEMENT.

Data Sharing Statement